Setting up manufacturing facilities—from cleanrooms and reactors to QC labs—is capital-intensive and time-consuming. Contract manufacturing enables pharma companies to avoid large fixed capital expenditures, instead paying per batch or project. This asset-light approach accelerates scale-up and conserves cash flow for formulation, marketing, and regulatory affairs.
